EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

Pharmacokinetic similarity of switching SAR341402 insulin aspart biosimilar and NovoLog insulin aspart versus continuous use of NovoLog in adults with type 1 diabetes: The GEMELLI X trial

Viral N Shah iD, Amer Al-Karadsheh, Cathy Barnes, Jose Mandry, Samer Nakhle, Karin Wernicke-Panten, Daniel Kramer, Wolfgang Schmider, Suzanne Pierre, Lenore Teichert, Baerbel Rotthaeuser, Bhaswati Mukherjee iD und 1 weitere

Diabetes, Obesity and Metabolism · 2024

DOI: 10.1111/dom.15341 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Viral N Shah und 12 weiteren Autor:innen. Beteiligte Einrichtung: Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals, Diabetes Mellitus, Type 1. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Sanofi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To assess whether multiple switches between SAR341402 biosimilar insulin aspart (SAR‐Asp) and the insulin aspart reference product (NovoLog; NN‐Asp) leads to equivalent pharmacokinetic (PK) exposure compared with continuous use of NN‐Asp in adults with type 1 diabetes (T1D). Materials and Methods This multicentre, open‐label, phase 3 study randomized (1:1) 210 subjects with T1D treated with once‐daily insulin glargine U100 as basal insulin to four 4‐week periods of alternating multiple daily injections of SAR‐Asp and NN‐Asp (NN‐Asp for the first 4 weeks, SAR‐Asp in the last 4 weeks; switching group) versus 16 weeks of continuous NN‐Asp (non‐switching group). At week 16, a single dose (0.15 U/kg) of SAR‐Asp in the switching group ( n = 95) or NN‐Asp in the non‐switching group ( n = 105) was given in the morning before breakfast. Primary PK endpoints were area under the plasma concentration curve (AUC) and maximum plasma concentration (C max ) of SAR‐Asp versus NN‐Asp after the single dose at week 16.

Results

The extent of PK exposure was similar between the two treatments (SAR‐Asp in the switching group and NN‐Asp in the non‐switching group) at week 16, with point estimates of treatment ratios close to 1. The 90% confidence intervals for AUC treatment ratios were contained within 0.8‐1.25. For C max in the primary analysis set, the upper confidence limit was 1.32. This was because of the profiles of three participants with implausible high values. A prespecified sensitivity analysis excluding implausible values showed results contained within 0.8‐1.25.

Conclusions

PK exposure of SAR‐Asp (switching group) and reference NN‐Asp (non‐switching group) were similar, supporting interchangeability between these two insulin aspart products.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biosimilar PharmaceuticalsDiabetes Mellitus, Type 1AdultHumansBlood GlucoseHypoglycemic AgentsInsulinInsulin AspartInsulin Glargine

Stichwörter der Autor:innen

GEMELLI XSAR341402biosimilarinsulin aspartinterchangeabilityswitches (max. 6)

Substanzen

Biosimilar PharmaceuticalsBlood GlucoseHypoglycemic AgentsInsulinInsulin AspartInsulin Glargine

Autor:innen und Institutionen

  • Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
  • Endocrine Center, Houston, Texas, USA.
  • Suncoast Clinical Research, New Port Richey, Florida, USA.
  • West Orange Endocrinology, Ocoee, Florida, USA.
  • Palm Medical Group, Las Vegas, Nevada, USA.
  • Sanofi, Frankfurt, Germany.

ORCID-Profile: Viral N Shah, Bhaswati Mukherjee, Timothy S Bailey

Förderung

  • Sanofi

Zitieren

APA

Shah, V. N., Al-Karadsheh, A., Barnes, C., Mandry, J., Nakhle, S., Wernicke-Panten, K., Kramer, D., Schmider, W., Pierre, S., Teichert, L., Rotthaeuser, B., Mukherjee, B., & Bailey, T. S. (2024). Pharmacokinetic similarity of switching SAR341402 insulin aspart biosimilar and NovoLog insulin aspart versus continuous use of NovoLog in adults with type 1 diabetes: The GEMELLI X trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15341

Vancouver

Shah VN, Al-Karadsheh A, Barnes C, Mandry J, Nakhle S, Wernicke-Panten K, et al. Pharmacokinetic similarity of switching SAR341402 insulin aspart biosimilar and NovoLog insulin aspart versus continuous use of NovoLog in adults with type 1 diabetes: The GEMELLI X trial. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15341

BibTeX
@article{Shah2024,
  author = {Shah, Viral N and Al-Karadsheh, Amer and Barnes, Cathy and Mandry, Jose and Nakhle, Samer and Wernicke-Panten, Karin and Kramer, Daniel and Schmider, Wolfgang and Pierre, Suzanne and Teichert, Lenore and Rotthaeuser, Baerbel and Mukherjee, Bhaswati and Bailey, Timothy S},
  title = {Pharmacokinetic similarity of switching SAR341402 insulin aspart biosimilar and NovoLog insulin aspart versus continuous use of NovoLog in adults with type 1 diabetes: The GEMELLI X trial},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2024},
  doi = {10.1111/dom.15341}
}
Kostenlos starten →